MX376370B - Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn. - Google Patents

Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn.

Info

Publication number
MX376370B
MX376370B MX2016000344A MX2016000344A MX376370B MX 376370 B MX376370 B MX 376370B MX 2016000344 A MX2016000344 A MX 2016000344A MX 2016000344 A MX2016000344 A MX 2016000344A MX 376370 B MX376370 B MX 376370B
Authority
MX
Mexico
Prior art keywords
immunoglobulin
conjugate
fragment
fcrn
maintains
Prior art date
Application number
MX2016000344A
Other languages
English (en)
Other versions
MX2016000344A (es
Inventor
In Young Choi
Sung Hee Hong
Sang Youn Hwang
Sung Youb Jung
Se Chang Kwon
Jong Soo Lee
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of MX2016000344A publication Critical patent/MX2016000344A/es
Publication of MX376370B publication Critical patent/MX376370B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un conjugado de polipéptido fisiológicamente activo y fragmento Fc de inmunoglobulina que comprende un polipéptido fisiológicamente activo unido a través de un enlazador no peptídico a un fragmento Fc de inmunoglobulina que tiene una región de unión a FcRn y mantiene la afinidad de unión intrínseca del fragmento Fc de inmunoglobulina, un método de preparación del conjugado, un método de mantenimiento de la afinidad de unión intrínseca del conjugado hacia FcRn y una composición que comprende el conjugado que mantiene la afinidad de unión intrínseca del fragmento Fc de inmunoglobulina hacia FcRn.
MX2016000344A 2013-07-12 2014-07-14 Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn. MX376370B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130082509 2013-07-12
PCT/KR2014/006328 WO2015005747A1 (ko) 2013-07-12 2014-07-14 FcRn 결합력이 유지되는 면역글로불린 Fc 결합체

Publications (2)

Publication Number Publication Date
MX2016000344A MX2016000344A (es) 2016-05-05
MX376370B true MX376370B (es) 2025-03-07

Family

ID=52280325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000344A MX376370B (es) 2013-07-12 2014-07-14 Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn.

Country Status (21)

Country Link
US (2) US20160152684A1 (es)
EP (1) EP3020732B1 (es)
JP (2) JP2016525099A (es)
KR (2) KR101872559B1 (es)
CN (2) CN105593243A (es)
AR (1) AR096890A1 (es)
AU (1) AU2014287879B2 (es)
CA (1) CA2917838C (es)
DK (1) DK3020732T3 (es)
EA (1) EA034297B1 (es)
ES (1) ES2799326T3 (es)
HU (1) HU231424B1 (es)
IL (1) IL243567B (es)
MX (1) MX376370B (es)
MY (1) MY180374A (es)
NO (1) NO20160182A1 (es)
PH (1) PH12016500111A1 (es)
PT (1) PT3020732T (es)
TW (1) TWI693236B (es)
UA (1) UA119644C2 (es)
WO (1) WO2015005747A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
SG11201608120TA (en) * 2014-03-31 2016-11-29 Hanmi Pharm Ind Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
TW201825123A (zh) * 2016-12-19 2018-07-16 南韓商韓美藥品股份有限公司 用於腦部靶向的長效蛋白質共軛物
KR102282240B1 (ko) 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
US20220273808A1 (en) * 2019-07-18 2022-09-01 Hanmi Pharm. Co., Ltd Novel method of preparing protein conjugate
KR102382593B1 (ko) * 2020-01-29 2022-04-05 고려대학교 산학협력단 pH-감응성 Fc 변이체

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
UA91325C2 (ru) * 2002-12-26 2010-07-26 Маунтин Вью Фармасьютикалз, Инк. Полимерные конъюгаты цитокинов, хемокинов, факторов роста, полипептидных гормонов и их антагонистов с сохраненной активностью рецепторного связывания
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
ES2438098T3 (es) * 2003-11-13 2014-01-15 Hanmi Science Co., Ltd. Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo
KR100609434B1 (ko) 2004-12-30 2006-08-03 한국항공우주연구원 트랜스버살 필터
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
ES2415604T3 (es) * 2007-05-30 2013-07-26 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR101200659B1 (ko) * 2008-07-23 2012-11-12 한미사이언스 주식회사 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체
AU2011225716A1 (en) * 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US8883134B2 (en) * 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
SG10201604564XA (en) 2011-06-10 2016-07-28 Hanmi Science Co Ltd Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
HRP20190265T1 (hr) * 2011-06-17 2019-04-05 Hanmi Science Co., Ltd. Konjugat koji sadrži oksintomodulin i fragment imunoglobulina i njegova uporaba
US9789202B2 (en) * 2011-09-05 2017-10-17 Hanmi Science Co., Ltd. Method for treating cancer using an interferon alpha conjugate
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada

Also Published As

Publication number Publication date
AU2014287879A1 (en) 2016-02-11
PH12016500111A1 (en) 2016-04-18
CA2917838A1 (en) 2015-01-15
CN116082528A (zh) 2023-05-09
AR096890A1 (es) 2016-02-03
JP6880278B2 (ja) 2021-06-02
JP2020125337A (ja) 2020-08-20
EA034297B1 (ru) 2020-01-27
PT3020732T (pt) 2020-06-25
MX2016000344A (es) 2016-05-05
KR102076718B1 (ko) 2020-02-12
CA2917838C (en) 2023-06-20
KR101872559B1 (ko) 2018-06-28
NO20160182A1 (en) 2016-03-02
JP2016525099A (ja) 2016-08-22
HUP1600206A2 (hu) 2016-05-30
WO2015005747A1 (ko) 2015-01-15
EP3020732A4 (en) 2016-12-28
HU231424B1 (hu) 2023-08-28
IL243567A0 (en) 2016-03-31
NZ716275A (en) 2021-09-24
US20220380437A1 (en) 2022-12-01
IL243567B (en) 2020-11-30
TW201546093A (zh) 2015-12-16
US20160152684A1 (en) 2016-06-02
ES2799326T3 (es) 2020-12-16
EP3020732B1 (en) 2020-03-18
EA201690114A1 (ru) 2016-07-29
CN105593243A (zh) 2016-05-18
TWI693236B (zh) 2020-05-11
EP3020732A1 (en) 2016-05-18
HK1221957A1 (en) 2017-06-16
KR20150008011A (ko) 2015-01-21
AU2014287879B2 (en) 2020-01-02
KR20180071241A (ko) 2018-06-27
DK3020732T3 (da) 2020-06-15
MY180374A (en) 2020-11-28
UA119644C2 (uk) 2019-07-25

Similar Documents

Publication Publication Date Title
MX376370B (es) Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX375441B (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
BR112016000680A2 (pt) conjugado de monômero de polipeptídeo biologicamente ativo e fragmento fc de imunoglobulina com eliminação mediada por receptor reduzida e método para a preparação do mesmo
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
MY209528A (en) Anti-il-33 antibodies and uses thereof
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
PH12016500943A1 (en) Aplnr modulatros and uses thereof
BR112015022978A8 (pt) tecnologias de multimerização
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201891573A1 (ru) Конъюгат терапевтических ферментов
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
PH12016500123A1 (en) Therapeutic fusion protein
EA201291065A1 (ru) Антитела против vla-4
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
EA201690855A1 (ru) Эндоглиновые пептиды для лечения фиброзных заболеваний
EA201991088A1 (ru) Связывающие пептиды
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение

Legal Events

Date Code Title Description
FG Grant or registration